Pfizer Stock Hits 10-Year Low: Investor Distrust in Covid-Era Giant

By -

 Pfizer stock’s struggles continued Wednesday, as shares of the healthcare titan dropped to their lowest level since before the Covid-19 pandemic, the latest dubious milestone for the battered stock that has failed to convert its vaccine boom into long-term sales growth.


 Pfizer said Wednesday it expects 2024 revenue to come in between $58.5 billion and $61.5 billion, representing roughly zero growth from 2023’s forecasts and coming in well below analysts’ average 2024 projected sales of $62.6 billion, according to FactSet.

Notably, Pfizer said it expects 2024 sales for its Covid products—Paxlovid pills and the Comirnaty vaccine—to be about $8 billion, a nearly 90% drop from the roughly $57 billion of revenue its Covid series brought in last year.

Shares of Pfizer tanked Wednesday as investors digested the subpar guidance, falling about 9% to below $26 in morning trading, hitting their lowest intraday share price since 2013.

That’s the largest single-day drop for Pfizer since January 2009.

BIG NUMBER


-50%. That’s about how much an investment in Pfizer has returned this year, including dividends, by far the weakest of any public American company valued at more than $100 billion. The S&P 500 is up more than 20%.

KEY BACKGROUND


Other publicly traded Covid vaccine makers have struggled mightily over the last two years as demand and government subsidies for the shots dried up. Shares of Moderna are down roughly 85% from their 2021 high and shares of Johnson & Johnson are down about 15% from their 2022 peak. As the pandemic-era stars fade, the stocks of pharmaceutical companies poised to profit off of the weight loss drug craze have soared; Mounjaro maker Eli Lilly and Ozempic maker Novo Nordisk became the two most valuable pharmaceutical companies in the world this year. Pfizer’s foray into weight loss treatments have yet to impress investors, and its stock dove 5% earlier this month after it revealed discouraging clinical results for its GLP-1 drug. On Tuesday, Pfizer said it expects regulators to approve its $43 billion acquisition of cancer drug maker Seagen, first announced in May. Seagen will account for about 5% of Pfizer’s 2024 sales, according to Wednesday’s guidance.


Comments

Post a Comment

Popular posts from this blog

Characters In BBC’s Documentary On TB Joshua Unknown To Us – Synagogue Church

By -
Image
  The Synagogue Church of all Nations (SCOAN) has countered the BBC documentary on the late Temitope Babatunde Joshua, known as TB Joshua, founder of SCOAN. SCOAN described the documentary against TB Joshua as unfounded, and that the characters interviewed in the report were unknown to the church. The church, in a statement signed by its Public Affairs Director, Mr Dare Adejumo, said the statement was aimed at disabusing public minds from the report. The News Agency of Nigeria (NAN) recalls that the BBC released a highly controversial and damning documentary on the late TB Joshua on Monday, accusing him of various crimes, including rape, against some members. SCOAN said, “BBC World Services investigative unit, code-named Africa Eye, came out this week with weird and strange episodes of atrocities against the late founder of SCOAN.” It said that to investigate and publish or broadcast reports was a central kernel of journalism, but to do so outside the ethics and fundamental principles
Read more

NBA Suspends Canada’s Joshua Primo For 4 Games For Exposing Himself To Women

By -
Image
  The NBA has suspended former San Antonio Spurs guard  Joshua Primo   for four games   ... after it says it found he exposed his private parts to multiple women. The league announced the ban on Friday morning ... saying an investigation into the free agent revealed he had "engaged in inappropriate and offensive behavior." NBA officials called his actions "conduct detrimental to the league." They did, however, note that they "did not find evidence that he engaged in any sexual or other misconduct apart from these brief exposures." "Primo maintains that his conduct was not intentional," the league said. Dr. Hillary Cauthen , Primo's former therapist, was the first to  bring the allegations  against Primo to light after she claimed last fall that he exposed himself to her on nine separate occasions. Dr. Cauthen's attorney,  Tony Buzbee , alleged the Spurs were aware of Primo's actions, but didn't take action. Cauthen went on to file
Read more

Sky Sports' On-Air Mix-Up: Chelsea Players Mistakenly Introduced as Axel Disasi Instead of Noni Madueke in Carabao Cup Semifinal

By -
Image
 Sky Sports were left red-faced after an on-screen graphic mistakenly introduced Chelsea defender Axel Disasi as Noni Madueke on Tuesday night. The pair were both the scoresheet as the Blues thrashed Middlesbrough 6-1 at Stamford Bridge in the second leg of the Carabao Cup semi-final to boo their place at Wembley. But when Disasi spoke to Sky Sports after the game, an on-screen graphic introduced him as Madueke instead. Madueke is four years younger than his Chelsea teammate, plays in a different role and is English, while Disasi is French. Viewers immediately spotted the mistake and took to social media to flag up the glaring error.  Sky Sports with a huge mistake as that is Axel Disasi, not Noni Madueke,' another added, while a third described the gaffe as a 'howler'. A fourth commented: 'Sky sports calling Disasi Madueke. They’ve done it again.' Disasi scored Chelsea's third goal in the 6-1 rout, converting Raheem Sterling's cross at the far post after th
Read more